Advertisement

An estimate of the burden of serious fungal diseases in Greece

  • M. N. Gamaletsou
  • M. Drogari-Apiranthitou
  • D. W. Denning
  • N. V. SipsasEmail author
Original Article

Abstract

Data on the epidemiology of serious fungal infections in Greece are scarce. Our aim was to calculate the burden of serious fungal diseases in Greece. A thorough literature search for papers reporting epidemiological data on serious fungal diseases in Greece was performed. Where no Greek data existed, we used a structured set of assumptions to estimate fungal disease burden, based on specific high-risk populations. Of the 10.8 million population, 85.5 % are adults and 27 % are over 60 years of age. The annual fungal disease estimates are as follows: 142,337 Greek women get recurrent vaginal thrush (2,632 cases/100,000 females); there are 889 cases of esophageal candidiasis (8.2 cases/100,000); annual incidence of Pneumocystis pneumonia is 112 cases; chronic pulmonary aspergillosis prevalence is 386 cases; there are 20,843 patients with allergic bronchopulmonary aspergillosis and 27,744 with severe asthma with fungal sensitization; candidaemia incidence is 541 cases (5.0/100,000); there are 81 cases of Candida peritonitis; invasive aspergillosis occurs in 1,125 patients. According to our calculations, 194,067 individuals (1.79 cases/100,000) in Greece suffer from serious fungal diseases each year. This is the first attempt to determine the burden of fungal diseases in Greece, and provides a crude estimate on its impact on public health.

Fungal diseases Burden Epidemiology Greece 

Notes

Compliance with ethical standards

Funding

This work was partly supported by the Special Account for Research Grants (ELKE) of the National and Kapodistrian University of Athens [grant number 70/3/11724].

Conflict of Interest

The authors declare that they have no conflict of interest related to this research.

Research involving human participants and/or animals

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

For this type of study, formal consent is not required.

References

  1. 1.
    Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC (2012) Hidden killers: human fungal infections. Sci Transl Med 4:165rv13CrossRefPubMedGoogle Scholar
  2. 2.
    Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M et al (2012) Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2163–2196CrossRefPubMedGoogle Scholar
  3. 3.
    Denning DW, Pleuvry A, Cole DC (2013) Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. Med Mycol 51:361–370CrossRefPubMedGoogle Scholar
  4. 4.
    Denning DW, Pleuvry A, Cole DC (2011) Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis. Bull World Health Organ 89:864–872CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Denning DW, Pleuvry A, Cole DC (2013) Global burden of chronic pulmonary aspergillosis complicating sarcoidosis. Eur Respir J 41:621–626CrossRefPubMedGoogle Scholar
  6. 6.
    Rodriguez-Tudela JL, Alastruey-Izquierdo A, Gago S, Cuenca-Estrella M, León C, Miro JM et al (2015) Burden of serious fungal infections in Spain. Clin Microbiol Infect 21:183–189CrossRefPubMedGoogle Scholar
  7. 7.
    Sinkó J, Sulyok M, Denning DW (2015) Burden of serious fungal diseases in Hungary. Mycoses 58(Suppl 5):29–33CrossRefPubMedGoogle Scholar
  8. 8.
    Ruhnke M, Groll AH, Mayser P, Ullmann AJ, Mendling W, Hof H et al (2015) Estimated burden of fungal infections in Germany. Mycoses 58(Suppl 5):22–28CrossRefPubMedGoogle Scholar
  9. 9.
    Spyrou AN (2009) Epidemiological study of leukemia incidence and mortality in the Greek population. Dissertation, Thessaloniki Aristotle UniversityGoogle Scholar
  10. 10.
    Aballéa S, Guelfucci F, Wagner J, Khemiri A, Dietz JP, Sobel J, Toumi M (2013) Subjective health status and health-related quality of life among women with recurrent vulvovaginal candidosis (RVVC) in Europe and the USA. Health Qual Life Outcomes 11:169CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Amouri I, Sellami H, Borji N, Abbes S, Sellami A, Cheikhrouhou F et al (2011) Epidemiological survey of vulvovaginal candidosis in Sfax, Tunisia. Mycoses 54:e499–e505CrossRefPubMedGoogle Scholar
  12. 12.
    Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA (2005) Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol 43:2155–2162CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Corsello S, Spinillo A, Osnengo G, Penna C, Guaschino S, Beltrame A et al (2003) An epidemiological survey of vulvovaginal candidiasis in Italy. Eur J Obstet Gynecol Reprod Biol 110:66–72CrossRefPubMedGoogle Scholar
  14. 14.
    Foxman B, Muraglia R, Dietz JP, Sobel JD, Wagner J (2013) Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from an internet panel survey. J Low Genit Tract Dis 17:340–345CrossRefPubMedGoogle Scholar
  15. 15.
    Grigoriou O, Baka S, Makrakis E, Hassiakos D, Kapparos G, Kouskouni E (2006) Prevalence of clinical vaginal candidiasis in a university hospital and possible risk factors. Eur J Obstet Gynecol Reprod Biol 126:121–125CrossRefPubMedGoogle Scholar
  16. 16.
    Buchacz K, Baker RK, Palella FJ Jr, Chmiel JS, Lichtenstein KA, Novak RM et al (2010) AIDS-defining opportunistic illnesses in US patients, 1994–2007: a cohort study. AIDS 24:1549–1559CrossRefPubMedGoogle Scholar
  17. 17.
    Smith E, Orholm M (1990) Trends and patterns of opportunistic diseases in Danish AIDS patients 1980–1990. Scand J Infect Dis 22:665–672CrossRefPubMedGoogle Scholar
  18. 18.
    Kofteridis DP, Valachis A, Velegraki M, Antoniou M, Christofaki M, Vrentzos GE et al (2014) Predisposing factors, clinical characteristics and outcome of Pneumonocystis jirovecii pneumonia in HIV-negative patients. J Infect Chemother 20:412–416CrossRefPubMedGoogle Scholar
  19. 19.
    Lagrou K, Maertens J, Van Even E, Denning DW (2015) Burden of serious fungal infections in Belgium. Mycoses 58(Suppl 5):1–5CrossRefPubMedGoogle Scholar
  20. 20.
    Dorgan E, Denning DW, McMullan R (2015) Burden of fungal disease in Ireland. J Med Microbiol 64:423–426CrossRefPubMedGoogle Scholar
  21. 21.
    Kordossis T, Avlami A, Velegraki A, Stefanou I, Georgakopoulos G, Papalambrou C et al (1998) First report of Cryptococcus laurentii meningitis and a fatal case of Cryptococcus albidus cryptococcaemia in AIDS patients. Med Mycol 36:335–339CrossRefPubMedGoogle Scholar
  22. 22.
    Velegraki A, Kiosses VG, Pitsouni H, Toukas D, Daniilidis VD, Legakis NJ (2001) First report of Cryptococcus neoformans var. gattii serotype B from Greece. Med Mycol 39:419–422CrossRefPubMedGoogle Scholar
  23. 23.
    Gamaletsou MN, Sipsas NV, Kontoyiannis DP, Tsiakalos A, Kontos AN, Stefanou I et al (2012) Successful salvage therapy of refractory HIV-related cryptococcal meningitis with the combination of liposomal amphotericin B, voriconazole, and recombinant interferon-γ. Diagn Microbiol Infect Dis 74:409–411CrossRefPubMedGoogle Scholar
  24. 24.
    Akinosoglou K, Melachrinou M, Siagris D, Koletsis E, Marangos M, Gogos CA et al (2014) Good’s syndrome and pure white cell aplasia complicated by Cryptococcus infection: A case report and review of the literature. J Clin Immunol 34:283–288CrossRefPubMedGoogle Scholar
  25. 25.
    Koufakis T, Tsapakidis K, Gabranis I (2014) A case of cryptococcal meningitis successfully treated with a combination of liposomal amphotericin-B and fluconazole. Hippokratia 18:380PubMedPubMedCentralGoogle Scholar
  26. 26.
    Smith NL, Denning DW (2011) Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma. Eur Respir J 37:865–872CrossRefPubMedGoogle Scholar
  27. 27.
    Tzanakis N, Anagnostopoulou U, Filaditaki V, Christaki P, Siafakas N, COPD group of the Hellenic Thoracic Society (2004) Prevalence of COPD in Greece. Chest 125:892–900CrossRefPubMedGoogle Scholar
  28. 28.
    Sichletidis L, Tsiotsios I, Gavriilidis A, Chloros D, Kottakis I, Daskalopoulou E et al (2005) Prevalence of chronic obstructive pulmonary disease and rhinitis in northern Greece. Respiration 72:270–277CrossRefPubMedGoogle Scholar
  29. 29.
    Zervas E, Loukides S, Kostikas K, Bakakaos P, Tzortzaki E, Gaga M, on behalf of Asthma Working Group of Hellenic Thoracic Society (2012) Asthma and asthma-like symptoms in Greece. The Greece asthma national prevalence survey. European Respiratory Society Annual Congress, September 1–5, 2012; Vienna, Austria, abstract P3936Google Scholar
  30. 30.
    Mastella G, Rainisio M, Harms HK, Hodson ME, Koch C, Navarro J et al (2000) Allergic bronchopulmonary aspergillosis in cystic fibrosis. A European epidemiological study. Eur Respir J 16:464–471CrossRefPubMedGoogle Scholar
  31. 31.
    Armstead J, Morris J, Denning DW (2014) Multi-country estimate of different manifestations of aspergillosis in cystic fibrosis. PLoS One 9:e98502CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Denning DW, O’Driscoll BR, Hogaboam CM, Bowyer P, Niven RM (2006) The link between fungi and severe asthma: a summary of the evidence. Eur Respir J 27:615–626CrossRefPubMedGoogle Scholar
  33. 33.
    Gioulekas D, Damialis A, Papakosta D, Spieksma F, Giouleka P, Patakas D (2004) Allergenic fungi spore records (15 years) and sensitization in patients with respiratory allergy in Thessaloniki-Greece. J Investig Allergol Clin Immunol 14:225–231PubMedGoogle Scholar
  34. 34.
    Dimopoulos G, Karabinis A, Samonis G, Falagas ME (2007) Candidemia in immunocompromised and immunocompetent critically ill patients: a prospective comparative study. Eur J Clin Microbiol Infect Dis 26:377–384CrossRefPubMedGoogle Scholar
  35. 35.
    Pratikaki M, Platsouka E, Sotiropoulou C, Douka E, Paramythiotou E, Kaltsas P et al (2011) Epidemiology, risk factors for and outcome of candidaemia among non-neutropenic patients in a Greek intensive care unit. Mycoses 54:154–161CrossRefPubMedGoogle Scholar
  36. 36.
    Gamaletsou MN, Walsh T, Zaoutis T, Pagoni M, Kotsopoulou M, Voulgarelis M et al (2014) A prospective, cohort, multicenter study of candidemia in hospitalized adult patients with hematological malignancies. Clin Microbiol Infect 20:O50–O57CrossRefPubMedGoogle Scholar
  37. 37.
    Montravers P, Mira JP, Gangneux JP, Leroy O, Lortholary O, AmarCand study group (2011) A multicentre study of antifungal strategies and outcome of Candida spp. peritonitis in intensive care units. Clin Microbiol Infect 17:1061–1067CrossRefPubMedGoogle Scholar
  38. 38.
    Lortholary O, Gangneux JP, Sitbon K, Lebeau B, de Monbrison F, Le Strat Y et al (2011) Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005–2007). Clin Microbiol Infect 17:1882–1889CrossRefPubMedGoogle Scholar
  39. 39.
    Perkhofer S, Lass-Flörl C, Hell M, Russ G, Krause R, Hönigl M et al (2010) The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients. Int J Antimicrob Agents 36:531–536CrossRefPubMedGoogle Scholar
  40. 40.
    Apostolidi EA, Gamaletsou MN, Markogiannakis A, Sipsas NV (2016) Epidemiology and outcome of invasive aspergillosis in patients with hematological malignancies: a Greek, single center, prospective, observational study (2014–2015). 7th Advances Against Aspergillosis Conference; 3–5 March 2016, Manchester, UK, abstract # P95Google Scholar
  41. 41.
    Herbrecht R, Bories P, Moulin JC, Ledoux MP, Letscher-Bru V (2012) Risk stratification for invasive aspergillosis in immunocompromised patients. Ann N Y Acad Sci 1272:23–30CrossRefPubMedGoogle Scholar
  42. 42.
    Lopez-Campos Bodineau JL, Fernandez GJ, Lara BA, Perea-Milla LE, Moreno L, Cebrian Gallardo JJ et al (2002) Analysis of admissions for chronic obstructive pulmonary disease in Andalusia in 2000. Arch Bronconeumol 38:473–478CrossRefPubMedGoogle Scholar
  43. 43.
    Guinea J, Torres-Narbona M, Gijon P, Munoz P, Pozo F, Pelaez T et al (2010) Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome. Clin Microbiol Infect 16:870–877CrossRefPubMedGoogle Scholar
  44. 44.
    Xu H, Li L, Huang WJ, Wang LX, Li WF, Yuan WF (2012) Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: a case control study from China. Clin Microbiol Infect 18:403–408CrossRefPubMedGoogle Scholar
  45. 45.
    Drogari-Apiranthitou M, Skiada A, Petrikkos G (2016) Epidemiology of mucormycosis in Greece; results from a 10-year multicentre nationwide survey. 26th European Congress of Clinical Microbiology and Infectious Diseases, 9–12 April 2016, Amsterdam, Nederland, Abstract #P0371Google Scholar
  46. 46.
    Ifanti AA, Argyriou AA, Kalofonou FH, Kalofonos HP (2013) Financial crisis and austerity measures in Greece: Their impact on health promotion policies and public health care. Health Policy 113:8–12CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • M. N. Gamaletsou
    • 1
    • 3
  • M. Drogari-Apiranthitou
    • 2
  • D. W. Denning
    • 1
  • N. V. Sipsas
    • 3
    Email author
  1. 1.The National Aspergillosis CentreUniversity Hospital of South Manchester, The University of Manchester and Manchester Academic Health Science CentreManchesterUK
  2. 2.Infectious Diseases Research Laboratory, 4th Dept. of Internal Medicine, Medical SchoolNational and Kapodistrian University of AthensAthensGreece
  3. 3.Infectious Diseases Unit, Pathophysiology Department, Medical SchoolNational and Kapodistrian University of AthensAthensGreece

Personalised recommendations